Brief: Nordic Nanovector Betalutin Receives Fast-Track Designation From US FDA

Thor Medical ASA

29/06/2020 06:32

June 29 (Reuters) - Nordic Nanovector ASA  NANOV.OL :
    * NORDIC NANOVECTOR'S BETALUTIN® RECEIVES FAST-TRACK
DESIGNATION
FROM US FDA
    * US FOOD AND DRUG ADMINISTRATION (FDA) GRANTS FAST TRACK
DESIGNATION FOR INVESTIGATING BETALUTIN ( 177 LU LILOTOMAB
SATETRAXETAN) FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR
REFRACTORY MARGINAL ZONE LYMPHOMA (MZL)
    * IS EVALUATING OPPORTUNITY TO DEVELOP BETALUTIN® AS A
SINGLE-AGENT TREATMENT FOR MZL, A RARE TYPE OF NON-HODGKIN'S
LYMPHOMA (NHL)
    * BETALUTIN® HAS DEMONSTRATED A VERY PROMISING CLINICAL
EFFECT IN
NINE MZL PATIENTS IN PHASE 1/2A LYMRIT 37-01 TRIAL

Source text for Eikon:  ID:nObiY6X7fa 
Further company coverage:  NANOV.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))